ECE2020 ePoster Presentations Thyroid (122 abstracts)
Clinical presentation and prognosis of patients with medullary thyroid cancer
Federica de Cicco 1 , Roberta Modica 2 , Livia Barba 2 , Filomena Bottiglieri 2 , Roberto Minotta 2 , Antongiulio Faggiano 3 & Annamaria Colao 2
1Endocrinology Unit ‘Federico II’ University, Naples, Italy, Department of Clinical Medicine and Surgery, Napoli, Italy; 2Endocrinology Unit, ‘Federico II’ University, Department of Clinical Medicine and Surgery, Napoli, Italy; 3Sapienza University, Department of Experimental Medicine, Roma, Italy
Medullary thyroid carcinoma (MTC) is a rare type of tumor that originates from parafollicular C-cells and accounts for 3–4% of all malignant thyroid neoplasms. MTC presents as sporadic (75–80%) or inherited tumors (20–25%). Hereditary MTC is part of multiple endocrine neoplasia type 2 (MEN2). Aim of the study was to describe clinical presentation, prognosis and therapy of sporadic MTC patients. Sixty-seven patients (pts) with histologically confirmed MTC referred to ENETS Center of Excellence of Naples, Endocrinology Unity of Federico II University between 2010–2018 were evaluated. MEN-2-inherited MTC were excluded. Clinical-pathological data, therapy and survival were retrospectively reviewed. Mean age at diagnosis was 51.4 ± 15.1 years. Mean calcitonin concentrations at diagnosis were 4101 ± 7801 pg/ml, resulting above the upper limits of the normal range in all cases, 11% with a slight increase of basal calcitonin had a calcium-stimulated test. Thyroid FNC was positive in 59.6%. Disease stage was I in 37.3%, II in 29.8%, III in 22.4% and IV in 7.4%. First-line therapy was surgery in all cases, radical surgery in 75%. Disease relapse occurred in 20 of those who had radical surgery (29.8%) while a second surgey or more was performed in 8.9%. Systemic therapy included pasireotide in 28.3%, everolimus in 10.4%, vandetanib in 13%. Median PFS was 132 months (95% CI, 61–203). Median survival was not reached. Calcitonin concentrations were increased in all cases at diagnosis but highly variable. MTC patients have substantially a favorable and long-time survival. In patients with metastases many different systemic therapies can be considered.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more